Tsai lauds Taiwan’s biotech innovation and development

2020/07/27

President Tsai Ing-wen said July 23 Taiwan’s biomedical industry has grown from strength to strength in recent years as a result of farsighted government policymaking, spotlighting her administration’s commitment to developing high-growth sectors of the economy.
 
 Biomedical technology has been a top priority in Taiwan’s national development strategy since she became president in 2016, Tsai said. Over the past few years the country has conducted over 300 clinical trials, 80 percent of which involved multinational firms, while local biomedical industry revenues grew 8.7 percent in 2019, with total investment exceeding NT$55.1 billion (US$1.84 billion), she added.
 
 Tsai made the remarks during the opening ceremony of the 2020 Bio Asia-Taiwan International Conference and Exhibition jointly organized by Taipei-based Taiwan Bio Industry Organization and Washington-headquartered Biotechnology Innovation Organization in Taipei City. Around 2,000 participants from 600 plus companies across the world are taking part in the six-day event, while 3,500 matchmaking sessions are scheduled to link the best and brightest domestic firms with buyers from abroad.
 
 According to Tsai, the annual conference is taking place as scheduled despite the COVID-19 pandemic thanks to the success of Taiwan’s disease-fighting measures and the collective efforts of the government and people.
 
 It is a great opportunity to swap notes on vaccine development and other ways to combat coronavirus, Tsai said, adding the country is more than willing to share the Taiwan Model for managing COVID-19 with the rest of the world.

Source: Taiwan Today (https://taiwantoday.tw/index.php)